CD274 and neoplasm: However, identifying novel biomarkers for optimizing the therapeutic impact of immunotherapy is still in an urgent need since the existing indicators, such as PD-L1 and TMB, which rely on tumor tissue biopsy, still cannot meet the clinical needs due to the lack of invasive examination, inconsistent detection standards, and inability to detect dynamically.